Asset profile
BMF-219
Small molecule
Evidence outlook · lead readout
NCT05731544 · Type 2 Diabetes Mellitus
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05731544: The study used randomization, double blinding, placebo control, and enrolled 443 participants; its primary efficacy measure was change in HbA1c, a clinically relevant regulator-accepted diabetes endpoint, alongside safety and pharmacokinetic assessments. Because results are not posted, whether the primary endpoint was met cannot be determined, so the evidence remains limited despite the controlled design.
Also in development:Non-Small Cell Lung Cancer · Phase 1
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
March 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchJune 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.